What patient population is most likely to benefit from pill in pocket strategy for management of paroxysmal atrial fibrillation in an unmonitored setting?   

Ideal patients are those with structurally normal hearts, no ischemia, and no renal impairment. For pill-in-the-pocket anti-arrhythmic therapy, I don't think an adjunctive AV node blocker is required for single-dose administration. Most patients who use pill-in-the-pocket antiarrhythmic therapy are...